14th Jan 2026 18:53
Oxford BioMedica PLC - Oxford, England-based gene and cell therapy developer - Says it notes recent press speculation and that it has received an unsolicited approach, regarding a possible cash takeover offer, from EQT X EUR SCSp and EQT X USD SCSp, funds managed by EQT Fund Management Sarl. Says it and EQT are in preliminary discussions to explore whether EQT could make a proposal which OXB's board would want to recommend. Previous unsolicited proposals from EQT have been rejected, as OXB's board believed they undervalued it and its prospects. Company "strongly" advises shareholders to take no action at this time.
Current stock price: 748.71 pence, up 1.3% on Wednesday in London
12-month change: up 91%
By Emma Curzon, Alliance News reporter
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Oxford Biomedica